Table 2.

Univariate and Multivariate Cox Regression analysis of overall survival and Recurrence-free survival in HCC patients (242 cases, GSE14520 dataset).

Variables		Overall survival	*P-Value	Recurrence-free survival	*P-Value
		HR (95%CI)		HR (95%CI)
Univariate analysis
Gender	Male vs. female	0.538(0.261-1.110)	0.094	0.424(0.223-0.807)	0.009
Age(years)	>55 vs. <=55	0.759(0.484-1.191)	0.231	1.022(0.714-1.464)	0.905
Tumor size(cm)	>5 vs. <=5	1.953(1.303-2.928)	0.001	0.713(0.504-1.008)	0.055
TNM staging	I/II vs. III	0.275(0.177-0.428)	<0.001	2.215(1.499-3.274)	<0.001
Serum AFP level(ng/ml)	>300 vs <=300	1.686(1.126-2.527)	0.011	0.761(0.543-1.067)	0.113
ALT(U/L)	>50 vs <=50	0.866(0.579-1.295)	0.483	0.724(0.517-1.014)	0.060
BCLC staging	0-A vs. B-C	3.692(2.381-5.726)	<0.001	2.647(1.803-3.888)	<0.001
CLIP staging	0 vs 1-5	2.194(1.384-3.478)	0.001	1.577(1.085-2.234)	0.016
Multinodular	Yes vs. no	0.599(0.385-0.931)	0.023	0.734(0.495-1.088)	0.124
Cirrhosis	Yes vs. no	5.093(1.255-20.671)	0.023	0.499(0.233-1.068)	0.074
SNRPD1	High vs. low	0.535(0.356-0.803)	0.003	0.695(0.496-0.973)	0.034
Multivariate analysis
Gender	Male vs. female			0.516(0.269-0.990)	0.047
Age(years)	>55 vs. <=55
Tumor size(cm)	>5 vs. <=5	0.945(0.517-1.727)	0.544
TNM staging	I/II vs. III	1.362(0.625-2.971)	0.322	0.976(0.524-1.816)	0.780
Serum AFP level(ng/ml)	>300 vs <=300	1.366(0.695-2.686)	0.741
ALT(U/L)	>50 vs <=50
BCLC staging	0-A vs. B-C	5.381(2.985-9.700)	<0.001	2.496(1.697-3.672)	<0.001
CLIP staging	0 vs 1-5	1.751(0.787-3.894)	0.274	1.136(0.741-1.742)	0.330
Multinodular	Yes vs. no	2.012(1.082-3.740)	0.027
Cirrhosis	Yes vs. no	0.206(0.050-0.839)	0.028
SNRPD1	High vs. low	1.968(1.266-3.060)	0.003	1.299(0.878-1.920)	0.042

Abbreviations: HR, hazard ratio; CI, confidential interval; AFP - alpha fetoprotein, TNM - tumor, node, metastasis; ALT, alanine aminotransferase. BCLC, Barcelona Clinic Liver Cancer. *P-Value<0.05 were considered statistically significant.